Posters

      3D‐Pictogram of Risk Measures in Epidemiology

      Kaelin, E.; Sperisen, P.
      Conference date
      Jun 23, 2010
      Conference name
      Society for Epidemiologic Research (SER) 2010
      Link to more information
      Link to more information
      Topic
      Summary

      The population health impact of an exposure risk is described as the absolute or relative number of individuals who developed disease due to the exposure. Several risk measures have to be combined to obtain these estimates: The absolute risk in the unexposed population, the relative risk, the population size, and the exposure prevalence. Previous attempts to visualize these dimensions together have failed to consider the exposure prevalence. If the exposure prevalence is known, then the number of cases attributable to the exposure is determined using Levin’s formula. A 3-dimensional (3D) plot enables global visualization of the attributable cases in the exposed population together with the relative risk, along with the exposure prevalence. If, moreover, the uncertainty of the absolute and relative risks can be estimated from the literature, then the 3D plot is extended to a 3D ellipsoid, representing confidence volumes of the attributable cases. The 3D pictogram enables illustration of the different exposures/diseases in comparison and visualization of the health impact in terms of attributable cases. The 3D pictogram is produced using the R package “RGL” with Microsoft Excel to capture the data. The simultaneous visualization of population impact of different exposures/diseases allows for a comprehensive assessment of relevant risk dimensions. Thus, the 3D pictogram can be helpful for public health discussions and prioritization of health policies by supporting communication, comparison, and interpretation of different exposures and risks. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.